Corcept Therapeutics (NASDAQ:CORT) Insider William Guyer Sells 20,000 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider William Guyer sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $40.97, for a total value of $819,400.00. Following the sale, the insider directly owned 2,231 shares in the company, valued at $91,404.07. The trade was a 89.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

William Guyer also recently made the following trade(s):

• On Friday, March 20th, William Guyer sold 11,767 shares of Corcept Therapeutics stock. The stock was sold at an average price of $36.01, for a total value of $423,729.67.
• On Wednesday, March 4th, William Guyer sold 8,233 shares of Corcept Therapeutics stock. The stock was sold at an average price of $35.99, for a total value of $296,305.67.
• On Tuesday, February 3rd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $40.87, for a total value of $817,400.00.

Corcept Therapeutics Trading Up 0.4%

Shares of NASDAQ CORT opened at $41.87 on Thursday. The business’s 50 day moving average is $37.54 and its two-hundred day moving average is $58.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.92 and a quick ratio of 2.85. Corcept Therapeutics Incorporated has a 1-year low of $28.66 and a 1-year high of $91.00. The stock has a market capitalization of $4.45 billion, a P/E ratio of 51.06 and a beta of 0.25.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.13). The company had revenue of $202.13 million for the quarter, compared to the consensus estimate of $254.94 million. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The company’s revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.26 earnings per share. As a group, research analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Negative Sentiment: Multiple securities class-action filings and firm solicitations allege misstatements related to FDA data concerns and investor losses, and several firms are reminding shareholders of an April 21, 2026 lead‑plaintiff deadline. This amplifies potential litigation risk and headline pressure on CORT. Corcept (CORT) Class Action Alleges Misstatements on FDA Data Concerns – Hagens Berman
• Negative Sentiment: Numerous plaintiff firms (Rosen, Kahn Swick & Foti, Pomerantz, Bronstein Gewirtz & Grossman, Kaplan Fox, Rosen, Gross, others) are actively soliciting Corcept investors and urging lead‑plaintiff filings for the same class period — increasing the likelihood of consolidated litigation and associated distraction/costs. ROSEN deadline alert
• Negative Sentiment: Insider sale: director William Guyer sold 20,000 shares at ~$40.97 under a pre‑arranged Rule 10b5‑1 plan (proceeds ~$819K), leaving him with ~2,231 shares — an ~90% decline in his holding. Large insider sales can be viewed negatively even if pre‑planned. SEC filing: Guyer sale

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. HC Wainwright cut their target price on Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, March 25th. Zacks Research cut Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Canaccord Genuity Group upped their target price on Corcept Therapeutics from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. UBS Group assumed coverage on Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price on the stock. Finally, Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.67.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp lifted its holdings in Corcept Therapeutics by 0.5% during the fourth quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company’s stock worth $103,915,000 after buying an additional 15,656 shares during the period. Geode Capital Management LLC lifted its holdings in Corcept Therapeutics by 38.0% during the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after buying an additional 734,646 shares during the period. Morgan Stanley lifted its holdings in Corcept Therapeutics by 34.1% during the fourth quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company’s stock worth $55,404,000 after buying an additional 405,081 shares during the period. AQR Capital Management LLC lifted its holdings in Corcept Therapeutics by 546.9% during the third quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock worth $125,264,000 after buying an additional 1,274,215 shares during the period. Finally, TD Asset Management Inc lifted its holdings in Corcept Therapeutics by 4.0% during the fourth quarter. TD Asset Management Inc now owns 994,844 shares of the biotechnology company’s stock worth $34,621,000 after buying an additional 38,708 shares during the period. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.